Research & Education

EGFR-Mutant Lung Cancer in 2018

May 8, 2018 at 9:00PM EDT

This webinar will review the current data and best practices for treatment of stage IV EGFR mutation-positive lung cancer.

Thymoma Update: 2018

April 24, 2018 at 7:00 PM CEST - Recording Available

This webinar focuses on the current management of thymic malignancies - from early stage to advanced stage disease.

Genomic Analysis of Plasma Cell-Free DNA for Lung Cancer Management: An Imperfect Biomarker, But We Love It Anyway

April 10, 2018 at 9:00PM EDT - Recording Available

Plasma cell-free DNA is a compelling but complex biospecimen which we now use routinely in the care of lung cancer patients.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors - 2018

March 29, 2018 at 10:00AM JST - Recording Available

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors 2018

March 20, 2018 at 7:00PM CET - Recording Available

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."

Novel EGFR TKIs for Advanced EGFR Mutant Advanced NSCLC

March 13, 2018 at 7:00 P.M. CET (Central European Time) - Recording Available

In patients with advanced EGFR mutant NSCLC, recent data on second generation EGFR TKI dacomitinib and third-line generation EGFR TKI osirmetinib shows improved efficacy when compared to first generation drugs such as gefitinib or erlotinib.

Immunotherapy for Early and Locally-Advanced Non-Small Cell Lung Cancer

March 13, 2018 at 9:00 P.M. EDT - Recording Available

Immunotherapy now has become an integral part of the management of advanced NSCLC.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors 2018

March 8, 2018 at 9:00 P.M. EST - Recording Available

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."

Mesothelioma Update

February 27, 2018 at 9:00PM EST - Recording Available

After attending this session attendees will be able to address the current state-of-the-art for treatment of malignant pleural mesothelioma.

Treatment Strategies for ROS1 Non-Small Cell Lung Cancer

February 6, 2018 at 7:00PM CET (Central European Time) - Recording Available

Recent advances in NSCLC treatment include the identification of targetable molecular subtypes beyond EGFR and ALK. ROS1 rearrangement is a distinct molecular subgroup of NSCLC patients with active therapeutic approaches.

Pages